Ibrutinib
- Generic Name
- Ibrutinib
- Brand Names
- Imbruvica
- Drug Type
- Small Molecule
- Chemical Formula
- C25H24N6O2
- CAS Number
- 936563-96-1
- Unique Ingredient Identifier
- 1X70OSD4VX
- Background
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell ...
- Indication
Ibrutinib is indicated for the treatment of the following conditions.
Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Waldenström's macroglobulinemia
Chronic graft-versus-host disease (cGVHD)
Mantle cell lymphoma (MCL)
Marginal zone lymphoma (MZL)
- Associated Conditions
- Chronic Graft-Versus-Host Disease, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma (MZL), Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Steroid-dependent chronic graft-versus-host disease, Waldenström's Macroglobulinemia (WM), Steroid refractory Chronic graft versus host disease
- Associated Therapies
- -
Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 75
- Registration Number
- NCT03731234
- Locations
- 🇮🇹
Ospedale di Castelfranco Veneto - Oncoematologia IOV, Castelfranco Veneto, Treviso, Italy
🇮🇹A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C. Ematologia, Alessandria, Italy
🇮🇹Università Politecnica delle Marche- Clinica di Ematologia, Ancona, Italy
A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2022-01-03
- Lead Sponsor
- Janssen-Cilag S.p.A.
- Target Recruit Count
- 312
- Registration Number
- NCT03720561
- Locations
- 🇮🇹
Div.Clinicizzata EmatologiaconTrapiantodi MidolloOsseo P.O.Rodoligo AOUPoliclinico-Vittorio Emanuele, Catania, Italy
🇮🇹S.C. Ematologia Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy
🇮🇹Unità Funzionale di Ematologia Azienda ospedaliero-universitaria Careggi, Firenze, Italy
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT03710772
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
- Conditions
- Interventions
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 30
- Registration Number
- NCT03708003
- Locations
- 🇨🇭
Kantonsspital Aarau, Aarau, Switzerland
🇨🇭IOSI - Ospedale San Giovanni, Bellinzona, Switzerland
🇨🇭Universitätsspital Basel, Basel, Switzerland
Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)
- Conditions
- Interventions
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT03703167
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 14
- Registration Number
- NCT03702725
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸The Ohio State University Wexner Medical Center/James Cancer Hospital, Columbus, Ohio, United States
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
- First Posted Date
- 2018-10-10
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 720
- Registration Number
- NCT03701282
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States
🇺🇸Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States
MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2024-08-28
- Target Recruit Count
- 175
- Registration Number
- NCT03697512
- Locations
- 🇫🇷
CHU de Tours - Hôpital Bretonneau, Tours, Cedex 01, France
🇮🇹Ospedale San Raffaele, Milano, MI, Italy
🇮🇹Università degli Studi di Roma La Sapienza, Roma, Italy
Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT
- Conditions
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 2
- Registration Number
- NCT03689894
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 136
- Registration Number
- NCT03684694
- Locations
- 🇺🇸
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
🇬🇧The Christie NHS Foundation Trust, Manchester, United Kingdom
🇫🇷Centre Hospitalier Lyon Sud, Pierre-Bénite, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.